News

InSysBio expert modelers Dr. Galina Lebedeva, Dr. Tatiana Karelina, Dr. Evgeny Metelkin and Dr. Oleg Demin will give the course “Modeling for systems biology and biomedicine” at the Faculty of bioengineering and bioinformatics, Lomonosov Moscow State University.

InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced today an extension of a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for QSP modeling in systemic lupus erythematosus (SLE). The goal is to support the clinical development of anifrolumab, an investigational monoclonal antibody against the type I interferon receptor, by modeling the contributions of key cell types involved in the pathophysiology of lupus that are associated with the type I interferon dysregulation commonly seen with the disease.

InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the launch of Immune Response Template (IRT) online. IRT is a QSP platform of human immune system and a tool for development of custom QSP models related to immune response.

InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the launch of Alzheimer’s Disease (AD) Modeling Consortium. The aim of the consortium is the support of drug development in AD by consolidation of efforts of teams from various pharmaceutical companies in framework of development and application of AD QSP platform.

InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced the registration of legal entity in UK. InSysBio UK (INSYSBIO UK LIMITED) is located in Edinburgh.

InSysBio LLC (www.insysbio.com), a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a collaboration with GSK, one of the world's leading research-based pharmaceutical and healthcare companies, for development of QSP platform of Chronic Obstructive Pulmonary Disease (COPD).